Back to Results
First PageMeta Content
HIV/AIDS / Organofluorides / Antifungals / Triazoles / Yeasts / Cryptococcus neoformans / Cryptococcosis / Fluconazole / AIDS / Medicine / Biology / Health


Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa Joseph N. Jarvis1,2,3*, Thomas S. Harrison3, Stephen D. Lawn1,2, Graeme Meintjes4,5,6,
Add to Reading List

Document Date: 2013-08-07 12:45:16

Open Document

File Size: 579,38 KB

Share Result on Facebook

City

Glaxo Smith Kline / Bangui / Kinshasa / Coudeville / Cape Town / Natal / London / Khayelitsha / /

Company

Cryptococcal Active Surveillance Group / Wellcome Trust / GE / Goldman / NIAID AIDS Clinical Trials Group / Dupont / Mirza SA / Creative Commons / Stephens / /

Continent

Africa / /

Country

Central African Republic / Cambodia / South Africa / Thailand / Kenya / France / Uganda / United Kingdom / /

Currency

pence / ZAR / USD / /

/

Facility

National Institute of Allergy / Institute of Infectious Disease / Imperial College / University of Cape Town / National Institute / Flucon Tunnel / G. F. Jooste Hospital / St. George’s University of London / /

IndustryTerm

health care technologies / HIV therapy / therapy for those with CNS disease / treatment of HIV / therapy for those identified as having CNS disease / treatment of overt cryptococcal disease / prevention of cryptococcal disease / /

MarketIndex

Consumer Price / /

MedicalCondition

systemic fungal infections / advanced human immunodeficiency virus infection / TB / CNS disease / HIV / cryprococcal infections / severe immune deficiency / HIV-Associated Cryptococcal Meningitis / HIV-related opportunistic infections / AIDS-related opportunistic infections / bacterial meningitis / CSF infection / Cryptococcal meningitis / AIDS Associated Cryptococcosis / severe disease / cryptococcosis / fungal infections / HIV infection / primary cryptococcal meningitis / opportunistic infections / Prevent HIVAssociated Cryptococcal Meningitis / disease / primary systemic fungal infections / overt cryptococcal disease / AIDS Introduction Cryptococcal meningitis / cryptococcal disease / deep fungal infections / AIDS / HIV/AIDS / infection / meningitis / adult meningitis / /

MedicalTreatment

Antiretroviral Treatment / antiretroviral therapy / highly active antiretroviral therapy / immunotherapy / immunosuppression / /

Organization

Description Unit / Imperial College London / National Institute of Allergy and Infectious Diseases Mycoses / Department of Clinical Research / South African Mycology Reference Unit / Research Centre for Infection and Immunity / University of Cape Town / London School of Hygiene and Tropical Medicine / Faculty of Infectious and Tropical Diseases / National Institute for Communicable Diseases / Department of Medicine / Division of Clinical Sciences / Health Economics Unit / Desmond Tutu HIV Centre / University of London / London / National Institute of Allergy / G. F. Jooste Hospital / Institute of Infectious Disease and Molecular Medicine / /

Person

T. Mark Doherty / Beck JR / /

Position

original author / Editor / General / Author / ART General / /

Product

itraconazole / clotrimazole / fluconazole / amphotericin B / /

ProvinceOrState

Scarborough / /

PublishedMedium

Health Economics / PLoS ONE / Infection and Immunity / /

RadioStation

Elbireer AM / /

Region

sub-Saharan Africa / South Africa / southern Africa / /

Technology

health care technologies / /

URL

www.plosone.org / www.oanda / www.oanda.com / /

SocialTag